Story
CVS Health Outlook Raised to Positive by Moody's on Deleveraging Progress

Moody's Ratings has upgraded its outlook on CVS Health (NYSE:CVS) to 'Positive' from 'Stable,' citing significant progress in the company's health insurance business transformation and a steady decline in its financial leverage.
The ratings agency on Friday affirmed its existing ratings for the company, including the Baa3 rating for its senior unsecured notes, Ba1 for its junior subordinated notes, and Prime-3 for its commercial paper.
Key Drivers for the Outlook Change
The improved outlook is primarily driven by CVS's successful efforts to strengthen its financial position. According to Moody's, this was achieved through strategic actions in its health insurance segment, including reducing membership size, adjusting pricing and benefit designs, and exiting the individual health insurance market.
This operational pivot has led to a notable reduction in debt. Moody's estimates that CVS Health's total debt-to-EBITDA ratio stood at approximately 3.7x as of June 30, 2024. The agency noted this is a marked improvement from a peak of 5.0x at the end of 2022 and 4.4x at the close of 2023.
Strengths and Lingering Risks
AdCVS's Baa3 rating continues to be supported by its vast scale and leading market positions across pharmacy benefit management (PBM), retail pharmacy, and health insurance. The company benefits from broad market reach and favorable industry fundamentals, such as the consistent growth in prescription drug utilization.
However, Moody's highlighted several ongoing challenges. The company's health insurance operations, particularly in the Medicare Advantage space, face high operational risks and potential volatility. Furthermore, CVS faces regulatory uncertainty in its pharmacy and PBM businesses, with potential for reform legislation from the U.S. Congress in the future.
Path to a Ratings Upgrade
Moody's indicated that a future upgrade of CVS's credit rating could occur if the company demonstrates sustained strong operational performance across its core business segments.
A key condition for an upgrade would be maintaining a prudent financial policy and keeping its debt-to-EBITDA ratio consistently below 4.0x. Headquartered in Woonsocket, Rhode Island, CVS Health reported total revenue of $415 billion for the twelve months ending June 30, 2024.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.